New cocktail of immune drugs shows promise against tough prostate cancer
NCT ID NCT03493945
First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 22 times
Summary
This study tested three different combinations of immunotherapy drugs in 59 adults with castration-resistant prostate cancer or other advanced solid tumors. The goal was to see if the combinations could shrink tumors or lower PSA levels (a marker of prostate cancer) and to check for side effects. Participants received the drugs in 2-week cycles and were monitored closely. The study has completed, and results help guide future research on immune-based treatments for hard-to-treat cancers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.